Helmuth Van Es
Co-founder, CSO
Pharmacy
EUBIOS SRL ENGINEERING COMPANY
Netherlands
Biography
Dr. Helmuth van Es has been responsible for the creation of a number of biotechnology companies. He is co-founder of Galapagos where he has held various R & D positions including Head of Science at Galapagos where he and his team developed a powerful target discovery and validation RNAi platform and applied this to a range of disease areas such as allergy, osteoporosis, osteoarthritis, rheumatoid arthritis, Alzheimer and cystic fibrosis. His track-record includes international drug discovery and development management of start-up and mid-sized companies.
Research Interest
He currently serves on the board of Antabio an antibacterial drug development company and Hifibio an MIT, Broad, Harvard and ESPCI microfluidics spinout focussing on the development of therapeutic antibodies. In 2015 he co-founded Citryll an antibody drug development company targeting neutrophil extracellular traps (NETosis) for treatment of SLE, RA and other diseases. He received his PhD in medicine from the University of Amsterdam and did postdoctoral research at McGill University in Montréal.
